Drugs /

a166

Back to Drugs List

Overview

Clinical Trials

View Clinical Trials for a166

A166 has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating a166, 1 is phase 1/phase 2 (1 open).

ERBB2 Amplification, HER2 Deficient Expression, and HER2 Equivocal are the most frequent biomarker inclusion criteria for a166 clinical trials.

Breast carcinoma, gastric carcinoma, and malignant solid tumor are the most common diseases being investigated in a166 clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating A166
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating a166 and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Drug Target(s) [2]:
ERBB2

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.